Alexza Pharmaceuticals, Inc.  

(Public, NASDAQ:ALXA)   Watch this stock  
Find more results for Thomas S. Read
+0.01 (0.50%)
Mar 30 - Close
NASDAQ real-time data - Disclaimer
Currency in USD
Range 1.98 - 2.05
52 week 1.25 - 5.27
Open 2.00
Vol / Avg. 10,427.00/42,043.00
Mkt cap 39.00M
P/E     -
Div/yield     -
EPS -2.08
Shares 19.40M
Beta 1.01
Inst. own 35%
May 4, 2015
Q1 2015 Alexza Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Mar 10, 2015
Alexza Pharmaceuticals Inc at ROTH Conference
Mar 9, 2015
Q4 2014 Alexza Pharmaceuticals Inc Earnings Call
Mar 9, 2015
Q4 2014 Alexza Pharmaceuticals Inc Earnings Release
More events from DailyFinance »    

Key stats and ratios

Q4 (Dec '14) 2014
Net profit margin -461.28% -660.53%
Operating margin -499.59% -673.55%
EBITD margin - -612.53%
Return on average assets -42.25% -67.63%
Return on average equity - -
Employees 81 -
CDP Score - -


2091 Stierlin Ct
MOUNTAIN VIEW, CA 94043-4655
United States - Map
+1-650-9447000 (Phone)
+1-650-9447999 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money


Alexza Pharmaceuticals, Inc. (Alexza) is a pharmaceutical company focused on the research, development and commercialization of products for the acute treatment of central nervous system (CNS) conditions. Alexza�s product candidates are based on its technology, the Staccato system. The Staccato system vaporizes an excipient-free drug to form a condensation aerosol that, when inhaled, allows for systemic drug delivery. The Company has one product candidate in active development, AZ-002 (Staccato alprazolam), which is being developed for the treatment of acute repetitive seizures, sometimes called cluster seizures or ARS. Its product candidates not in active development are AZ-007 (Staccato zaleplon), AZ-104 (Staccato loxapine, low-dose) AZ-003 (Staccato fentanyl) and AZ-003 (Staccato fentanyl). The Company has retained all rights to the Staccato system and to its product candidates other than ADASUVE and AZ-104 (Staccato loxapine, low-dose).

Officers and directors

Thomas B. King President, Chief Executive Officer, Director
Age: 59
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
Mark K. Oki Senior Vice President, Finance, Chief Financial Officer, Secretary, Principal Financial Officer and Principal Accounting Officer
Age: 45
Bio & Compensation  - Reuters
Robert A. Lippe Chief Operating Officer, Executive Vice President - Operations
Age: 49
Bio & Compensation  - Reuters
Edwin S. Kamemoto Ph.D. Senior Vice President - Regulatory Affairs
Age: 61
Bio & Compensation  - Reuters
Michael J. Simms Senior Vice President - Operations and Manufacturing
Age: 51
Bio & Compensation  - Reuters
Isaac Stein Lead Independent Director
Age: 67
Bio & Compensation  - Reuters
J. Kevin Buchi Independent Director
Age: 59
Bio & Compensation  - Reuters
Deepika R. Pakianathan Ph.D. Independent Director
Age: 49
Bio & Compensation  - Reuters
J. Leighton Read M.D. Independent Director
Age: 63
Bio & Compensation  - Reuters
Gordon Ringold Ph.D. Independent Director
Age: 63
Bio & Compensation  - Reuters